CNPAX
Price
$72.99
Change
-$0.98 (-1.32%)
Updated
Jul 13 closing price
Net Assets
170.23B
SGAPX
Price
$20.07
Change
-$0.01 (-0.05%)
Updated
Jul 13 closing price
Net Assets
148.77M
Interact to see
Advertisement

CNPAX vs SGAPX

CNPAX vs SGAPX Comparison Chart in %
View a ticker or compare two or three
VS
CNPAX vs. SGAPX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CNPAX is a Hold and SGAPX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CNPAX has more cash in the bank: 170B vs. SGAPX (149M). CNPAX pays higher dividends than SGAPX: CNPAX (0.95) vs SGAPX (0.00). CNPAX was incepted earlier than SGAPX: CNPAX (24 years) vs SGAPX (13 years). SGAPX (1.13) is less costly to investors than CNPAX (0.74). SGAPX is a more actively managed with annual turnover of: 37.00 vs. CNPAX (23.00). CNPAX has a lower initial minimum investment than SGAPX: CNPAX (250) vs SGAPX (100000). CNPAX annual gain was more profitable for investors over the last year : 7.37 vs. SGAPX (-17.37). CNPAX return over 5 years is better than : 13.82 vs. SGAPX (-36.27).
CNPAXSGAPXCNPAX / SGAPX
Total Expense Ratio0.741.0074%
Annual Report Gross Expense Ratio0.741.1365%
Fund Existence24 years13 years-
Gain YTD5.325-4.653-114%
Front Load4%N/A-
Min. Initial Investment2501000000%
Min. Initial Investment IRAN/AN/A-
Net Assets170B149M114,094%
Annual Yield % from dividends0.950.00-
Returns for 1 year7.37-17.37-42%
Returns for 3 years34.17-19.20-178%
Returns for 5 years13.82-36.27-38%
Returns for 10 years115.9129.28396%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBDIX200.49N/A
N/A
Franklin Biotechnology Discovery A
VGHCX206.44N/A
N/A
Vanguard Health Care Inv
SCETX9.22N/A
N/A
Virtus Ceredex Small-Cap Value Eq I
SEFCX14.37N/A
N/A
SEI International Equity Y (SIT)
VREMX7.87N/A
N/A
Virtus SGA Emerging Markets Equity R6